Managing progressive renal disease before dialysis

Canadian Family Physician

Volumn 45, Issue APR., 1999, Pages 977-984

  Barrett, Brendan J ^a  

^a Health Sciences Centre St John's   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HYPERLIPIDEMIA; PRIMARY HEALTH CARE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DISEASE PROGRESSION; HUMANS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; PRIMARY HEALTH CARE; PROTEINURIA; RENAL DIALYSIS;

EID: 0033109860     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Canadian Organ Replacement Register. Annual report 1997. Volume 1: dialysis and renal transplantation. Ottawa, Ont: Canadian Institute for Health Information; 1997. p. 1-6.
2. Canadian Organ Replacement Register. Annual report 1997. Volume 1: dialysis and renal transplantation. Ottawa, Ont: Canadian Institute for Health Information; 1997. p. 5-3-5-5.
3. Mendelssohn DC, Chery A, for the Toronto Region Dialysis Committee. Dialysis utilization in the Toronto region from 1981-1992. Can Med Assoc J 1994;150:1099-105.
4. Barrett BJ, Parfrey PS, Morgan J, Barre P, Fine A, Goldstein M, et al. Prediction of early death in end-stage renal disease patients starting dialysis. Am J Kidney Dis 1997; 29:214-22.
5. Wahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988;318:1657-66.
6. Whelton PK, Jiang H, Perneger TV, Klag MJ. Kidney damage in "benign" essential hypertension. Curr Opin Nephrol Hypertens 1997;6:177-83.
7. Blantz RC, Gabbai F, Gushwa LC, Wilson CB. The influence of concomitant experimental hypertension and glomerulonephritis. Kidney Int 1987;32:652-63.
8. Kes P, Ratkovic-Gusic I. The role of arterial hypertension in progression of renal failure. Kidney Int Suppl 1996; 49(Suppl 55):S-72-S-74.
9. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12:1908-15.
10. Navis G, de Zeeuw D. Titrating for antiproteinuric effect the clue to renoprotection? J Hum Hypertens 1996;10:669-73.
11. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant 1996; 11:461-7.
12. Buckalew VM, Berg RL, Wang S-R, Porush JG, Rauch S, Schulman G. Prevalence of hypertension in 1,795 subjects with chronic renal disease: The Modification of Diet in Renal Disease Study baseline cohort Am J Kidney Dis 1996;28:811-21.
13. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123:754-62.
14. Zucchelli P, Zuccala A. Blood pressure control effects on the progression of chronic renal failure. Ren Fail 1993;15:339-42.
15. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
16. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
17. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987; 294:1443-7.
18. American Diabetes Association. American Diabetes Association consensus statement diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1996;19(Suppl 1):s103-6.
19. Mahr S, Levey AS, Beck GS, Caggiula AN, Hunsicker L, Kesek JW, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-84.
20. Apperloo AJ, deZeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997;51:793-7.
21. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension 1997;29:641-50.
22. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-62.
23. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7 year follow up study. Arch Intern Med 1996;156:286-9.
24. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 1998;128:982-8.
25. Giatras I, Lau J, Levey AS, for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997;127:337-45.
26. Aurell M, Bengtsson C, Bjorck S. Enalapril versus metoprolol in primary hypertension-effects on the glomerular filtration rate. Nephrol Dial Transplant 1997;12:2289-94.
27. Shiigai T, Hatori K, Iwamoto H, Owada A Long-term enalapril therapy in patients with chronic renal failure on a low-protein diet, Nephron 1998;79:148-53.
28. Navis G, Faber HJ, de Zeeuw D, de Jong PE. ACE inhibitors and the kidney: a risk benefit assessment Drug Safety 1996; 15:200-11.
29. Bannister KM, Weaver A Clarkson AR, Woodroffe AJ. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 1995; 111:184-93.
30. ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med 1994;154:1185-202.
31. Epstein M. Calcium antagonists and the progression of chronic renal failure. Curr Opin Nephrol Hypertens 1998;7:171-6.
32. Tatti P, Pahor M, Byington RP, DiMauro P, Guarisco R, Strollo G, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21:597-603.
33. Wahr S. Is there still a role for a diet very low in protein, with or without supplements, in the management of patients with end-stage renal failure? Curr Opin Nephrol Hypertens 1996;5:384-7.
34. Levin A Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the pre-dialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27:347-54.
35. Revicki DA Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for preanalysis chronic renal disease patients. Am J Kidney Dis 1995;25:548-54.
36. The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991;18:50-9.
37. Portoles J, Torralbo A Martin P, Rodrigo J, Herrero JA Barrientos A Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29:541-8.
38. Yagil Y. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Isr J Med Sci 1997;33:36-44.